Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette,...
March 09 2021 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”,
“We”, “Our” or “Inotiv”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services continues to invest in expanding services and adding
capacity to meet client needs and growth expectations. In line with
these goals, the Company has been expanding and further developing
its West Lafayette vivarium. Last month, the additional West
Lafayette capacity was successfully accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
International Council. The Company believes this is an important
step forward as it remains focused on strategic growth.
The AAALAC International Council on Accreditation commended
Inotiv’s West Lafayette facility for excellent institutional
support, specifically noting financial support for facilities,
infrastructure, continuing education and development of staff, an
engaged Institutional Animal Care and Use Committee (IACUC), and
exceptionally well-maintained facilities.
“We choose to make investments such as those to our West
Lafayette facility because they allow us to provide the speed and
quality that our clients deserve, while at the same time promoting
the highest possible standards of care and service,” said Company
President and Chief Executive Officer Robert Leasure, Jr. “We take
pride in all of our facilities being AAALAC accredited, even those
where it would not be required. We hold ourselves to that high
standard.”
The West Lafayette facility showcases advanced in vivo
capabilities, purpose-built to characterize pharmacologic and
toxicologic parameters of drug candidates. The vivarium utilizes
state of-the-art equipment including the Company’s Culex Automated
Pharmacology System and Empis System.
About the Company
Bioanalytical Systems, Inc., doing business as
Inotiv, is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. The Company’s products focus on
increasing efficiency, improving data, and reducing the cost of
taking new drugs to market. Visit inotivco.com for more information
about the Company.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic
on the economy, demand for our services and products and our
operations, including the measures taken by governmental
authorities to address the pandemic, which may precipitate or
exacerbate other risks and/or uncertainties and various other
market and operating risks, including those detailed in the
Company's filings with the U.S. Securities and Exchange
Commission.
Company Contact |
Investor Relations |
Bioanalytical Systems, Inc., dba Inotiv |
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
Kalle Ahl, CFA |
(765) 497-8381 |
(212) 836-9614 |
btaylor@inotivco.com |
kahl@equityny.com |
|
|
|
Devin Sullivan |
|
(212) 836-9608 |
|
dsullivan@equityny.com |
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024